Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence

INTRODUCTION: A number of disease-modifying therapies have been approved for use in relapsing-remitting multiple sclerosis (MS) in the past two decades. However, only few treatment options are available for patients with secondary progressive multiple sclerosis (SPMS). Siponimod has recently been ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabsabi, Sajida, Mikhael, Elio, Jalkh, Georges, Macaron, Gabrielle, Rensel, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148218/
https://www.ncbi.nlm.nih.gov/pubmed/35637684
http://dx.doi.org/10.2147/PPA.S221882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148218/
https://www.ncbi.nlm.nih.gov/pubmed/35637684
http://dx.doi.org/10.2147/PPA.S221882

Ejemplares similares